Background: Recent studies have reported a greater probability of vancomycin treatment failure in methicillinresistant Staphylococcus aureus (MRSA) bloodstream infections caused by strains with a vancomycin MIC ≥1.5 mg/L. However, previous reports included patients treated without adjustments based on vancomycin serum levels and with different methods to evaluate MICs, which may render different results.
Introduction
Staphylococcus aureus bacteraemia is one of the most significant causes of healthcare-related and community-acquired infections. 1 -3 A significant proportion of episodes are caused by methicillin-resistant S. aureus (MRSA) 4 -6 and vancomycin is the drug most frequently used to treat such episodes in many institutions.
The vast majority of MRSA isolates are susceptible to vancomycin; however, in recent years, several institutions have reported a creep in the MIC of vancomycin (vancomycin creep). 7 -9 Several authors have reported higher rates of clinical failure and mortality among patients with MRSA bacteraemia treated with vancomycin, mainly when caused by isolates with MICs ≥1.5 mg/L. 10 -13 In those papers the correlation with poor outcome is mainly based on MICs tested by the Etest method, which is not a standard test approved by the American Society for Microbiology. Vancomycin MICs differ depending on the method used for testing, either by the Etest or by the broth microdilution method. 12, 14 Moreover, articles evaluating the evolution of MRSA bacteraemias treated with vancomycin frequently included patients disregarding the adequacy of vancomycin treatment.
We compared the MICs obtained for vancomycin using the Etest and microdilution in a large number of microorganisms causing MRSA bacteraemia in a single institution. We also analysed clinical failure in vancomycin-treated patients at the different MICs obtained with each method, taking into account the serum vancomycin levels.
Patients and methods

Study period and patient selection
Gregorio Marañó n University General Hospital is a large teaching hospital serving an urban population of 715000 inhabitants. The microbiology laboratory processes blood cultures using the BACTEC 9240 system (Becton Dickinson Microbiology Systems, Sparks, MD, USA). Isolates were identified according to standard procedures and susceptibility testing was performed following the recommendations of the CLSI. 15 Although the design of our study is retrospective, all episodes of bacteraemia were recorded prospectively and the strains were stored at 2708C. For the in vitro study, strains causing MRSA bacteraemia from January 2005 to December 2009 were selected.
Determination of the vancomycin MIC
All stored MRSA strains (n¼361) were thawed to determine the vancomycin MIC simultaneously by microdilution and Etest using the same inoculum. Vancomycin MICs by microdilution were determined according to the CLSI recommendations using cation-adjusted Mueller-Hinton broth (Oxoid, Basingstoke, UK) with concentrations ranging between 0.06 and 32 mg/L. Vancomycin MICs by Etest were determined using commercialized strips with concentrations ranging from 0.016 to 256 mg/L (bioMérieux, France). A 0.5 McFarland inoculum was used. Readings were performed 24 h after incubation at 35 -378C in room air. An isolate was considered susceptible to vancomycin when the MIC was ≤2 mg/L. For the purpose of this study, Etest MICs ≥1.5 mg/L and microdilution MICs ≥1 mg/L were considered to be elevated. S. aureus ATCC 29213 and Enterococcus faecalis ATCC 29212 were used as control strains.
Clinical data
In order to assess baseline characteristics and clinical course, only those patients treated with vancomycin and from whom vancomycin serum levels had been determined at least once during treatment were selected. The following data were obtained: age, sex, pre-existing comorbidities, risk factors for MRSA bacteraemia, type of acquisition (community acquired, hospital acquired or healthcare related), source of bacteraemia, organs involved, clinical deterioration, initial dose of vancomycin, duration of therapy, serum concentration, microbiological response, clinical outcome and mortality. In order to compare the epidemiological and clinical characteristics, the patients were grouped according to the MIC value obtained using each method. A comparison of the outcome of patients with S. aureus bacteraemia caused by strains with an MIC ,1 versus ≥1 mg/L obtained by microdilution and an MIC ,1.5 versus ≥1.5 mg/L obtained by the Etest was performed.
Vancomycin serum levels were determined using the Abbott TDX-FLX automated fluorometric system (Abbott Laboratories, IL, USA), following the manufacturer's recommendations.
Definitions
Primary bacteraemia: patient with MRSA cultured from one or more blood cultures and not related to an infection at another site, according to the definitions of the CDC. 16 Severity of sepsis: the bone score was used. 17 Persistent bacteraemia: positive blood cultures after 5 days of effective antibiotic treatment.
Metastatic infection: parenchyma affected as a result of MRSA bacteraemia.
Complicated bacteraemia: presence of metastatic infection during hospitalization, attributable mortality or recurrent infection during the follow-up period. 18 Nosocomial acquisition: positive blood cultures in samples obtained .72 h after admission, with no evidence of disease on admission.
Healthcare related: when the patient had been hospitalized during the previous 3 months or routinely required medical assistance inside or outside the hospital (i.e. dialysis, chemotherapy).
Related death: death that could be attributed to MRSA bacteraemia as either the immediate or underlying cause.
Statistical analysis
The quantitative association between the vancomycin MIC values obtained by each method was assessed by means of linear correlation.
For the univariate analysis of the characteristics of patients with high and low vancomycin MICs, continuous variables were assessed using the Mann-Whitney test and qualitative variables were assessed using the Fisher's exact test or the x 2 test. A P value ,0.05 was considered significant. All statistical tests were two-tailed.
A multivariate logistic regression model was used to assess the independent effect of the vancomycin MIC and other factors on the outcome of patients with MRSA bacteraemia. A forward stepwise approach was followed, including as candidate variables all those that were significant in the univariate analysis. The results are presented as adjusted odds ratios with 95% confidence intervals. All statistical procedures were performed using SPSS version 15.0 (SPSS Inc., Chicago, IL, USA).
Ethics
The study was approved by the local Ethics Committee.
Results
During the study period, we recorded 361 episodes of MRSA bacteraemia. These episodes occurred in 309 patients: 104 had been treated with vancomycin and their vancomycin serum level had been determined at least once during treatment. 
Determination of vancomycin MICs
Clinical study
General characteristics of patients with MRSA bacteraemia
For the clinical study, 104 patients treated with vancomycin and for whom vancomycin serum levels had been determined at least once during the treatment period were selected ( Table 2 ). The mean age was 65+19 years and most patients were men (73.1%). A high proportion of patients (69.2%) had a non-fatal underlying condition (McCabe and Jackson). The mean Charlson comorbidity index was high (5.9+3). The acquisition of MRSA bacteraemia was nosocomial in 82 patients (78.8%), healthcare related in 20 (19.2%) and community acquired in 2 (1.9%). The most common source of bacteraemia was an intravenous catheter (48 patients; 46.2%), followed by primary sepsis (18 patients; 17.3%). A large proportion of patients (35; 33.7%) had at least severe sepsis (severe sepsis, shock or multiorgan failure) and 24 (23.1%) had persistent bacteraemia. Overall, 21 were admitted to the intensive care unit (ICU). Metastatic infection affected 42 patients (40.4%); the organs most commonly involved were the lungs (30 patients; 28.8%) and the kidneys, with 19 patients (18.3%) having renal failure. Overall, 73% of patients had vancomycin serum trough levels .10 mg/L and 41% had serum trough levels .15 mg/L. The median length of treatment with vancomycin was 14 (8 -19) days and 44 patients (42.3%) received vancomycin for .14 days. Four patients with endocarditis and five with bone or joint infection received rifampicin as the second antimicrobial agent. The median hospital stay was 22 (14 -39) days.
Characteristics of bacteraemic MRSA episodes according to vancomycin MIC value determined by Etest and microdilution
Etest MICs ≥1.5 mg/L and microdilution MICs ≥1 mg/L were considered to be elevated. A total of 68 patients (65.4%) had an Etest MIC ≥1.5 mg/L and 62 patients (59.6%) a microdilution MIC ≥1 mg/L. Sex, age, severity of underlying condition, acquisition and source of infection were similar in patients with low and high MICs determined with both methods (Table 2 ). There was no correlation between the vancomycin MIC and the severity of sepsis or between the vancomycin MIC and metastatic infection. Patients with persistent bacteraemia (24) frequently had high vancomycin MICs (19 with the Etest and 18 with microdilution), but the differences did not reach statistical significance (Etest, P ¼ 0.1; microdilution, P ¼ 0.08) ( Table 2 ). The trough vancomycin serum levels and length of hospital stay were similar in all groups.
The overall mortality was 39.4% and the related mortality was 26.9%. Factors associated with mortality in the univariate analysis were advanced McCabe and Jackson stage (P ¼ 0.03), high Charlson comorbidity index (P ¼ 0.02), severity of sepsis (P ¼ 0.005) and renal failure (P ¼ 0.02). Lung involvement and higher trough serum vancomycin levels (.20 mg/L) tended to be associated with higher mortality rates (P ¼ 0.07) ( Table 3) .
No correlation between mortality and any specific vancomycin MIC value was observed, whether determined by microdilution or Etest. The mortality rate according to an Etest MIC ,1.5 versus ≥1.5 mg/L was 36.6% versus 63.4% (P ¼ 0.73); the mortality rate according to a microdilution MIC ,1 versus ≥1 mg/L was 34.1% versus 65.9% (P ¼ 0.3) ( Table 4) . No effect of MIC on mortality was found, even when we selected patients with high MICs and low vancomycin levels (Tables 5-7) . For instance, in the 28 episodes with trough vancomycin serum levels ,10 mg/L, mortality was similar in patients with low MICs and in patients with high MICs by both methods. The mortality rate according to an Etest MIC ,1.5 versus ≥1.5 mg/L was 55.6% versus 44.4% (P ¼ 0.21); the mortality rate according to a Rojas et al.
microdilution MIC ,1 versus ≥1 mg/L was 44.4% versus 55.6% (P ¼ 0.5) ( Table 5 ). The mortality rate of the 361 episodes of MRSA bacteraemia was 44.6%. No correlation between mortality and the vancomycin MIC value was observed with any of the two different susceptibility testing methods, microdilution or Etest (Table 7) . Rojas et al.
Discussion
There was a poor correlation between the MICs of vancomycin for MRSA causing bloodstream infections as determined by the Etest and by microdilution. Neither technique could predict the clinical outcome of vancomycin-treated patients. S. aureus is one of the main causes of bloodstream infection and can be community acquired or healthcare related. 1 -3,19 A significant proportion of S. aureus isolates are resistant to methicillin in many areas of the world 1, 20, 21 and require treatment with glycopeptides, particularly vancomycin. Before 2006, MRSA isolates were considered susceptible to vancomycin when MICs were ≤4 mg/L; however, this breakpoint was decreased to ≤2 mg/L due to poor results in patients with infections caused by isolates with MICs .2 mg/L. 15, 22 The mortality of MRSA bacteraemia is reported to be between 20% and 39%. 6, 23 Risk factors for poor prognosis include the characteristics of the microorganism (e.g. Panton -Valentine leucocidin toxin) and patient-or treatment-related factors (older age, comorbidity, malignancy, delay in appropriate treatment and presence of bacteriuria). 4, 24, 25 Until recently, the effect of the vancomycin MIC on MRSA isolates was not considered a factor for poor prognosis in patients infected by susceptible microorganisms.
Several groups have described a progressive increase in the vancomycin MIC values for susceptible strains (vancomycin creep). 7 -9 Isolates with MICs ≥1.5 mg/L have been related to a worse clinical outcome than those with lower values. 10 -13 However, the MICs showing a better correlation with worse outcome were obtained using the Etest, although microdilution is the gold standard technique. 15 Several authors, however, have shown great disparity between MIC results, depending on 14 By Etest, 90.4% of the strains had a vancomycin MIC ≥1.5 mg/L compared with 3.1% by microdilution. Vancomycin MIC values obtained using the Etest are usually higher than those obtained using microdilution (0.5 -1.5 log 2 dilutions).
Our experience does not show a correlation between the MICs obtained using each technique. During the study period, 66.5% of episodes of MRSA bacteraemia at Gregorio Marañ ó n General Hospital were caused by strains with a vancomycin Etest MIC ≥1.5 mg/L. However, only 3.6% of the strains had values .1 mg/L when microdilution was used. Although a statistically significant linear correlation was detected between vancomycin MICs obtained by both techniques, the low value of the coefficient indicates that most of the information provided by these methods is largely independent and that neither can reliably predict the other. Adapting the Etest for routine use in microbiology laboratories would entail a significant increase in laboratory workload and cost, 26 and, in our opinion, should not be undertaken unless clear clinical data show the Etest to be a better predictor of outcome than microdilution.
Recent studies reported a greater probability of treatment failure in MRSA bloodstream infections caused by strains with a vancomycin MIC ≥1.5 mg/L. 11 -13 Most were based on MICs obtained using the Etest only and did not analyse whether this correlation persisted when vancomycin serum levels were inadequate (trough ,10 mg/L). Soriano et al. 11 analysed 414 episodes of MRSA bloodstream infection treated with vancomycin and reported a greater probability of treatment failure if the strains had an MIC ≥1.5 mg/L in the univariate analysis. Unfortunately, the study did not include data on vancomycin serum levels and, in the multivariate analysis, only the much more uncommon strains with an MIC value ≥2 mg/L were associated with greater mortality (OR, 6.39; 95% CI, 1.68-24.3; P,0.001).
11 Hsu et al. 12 analysed 92 MRSA strains obtained from different sources and suggested that MRSA bacteraemia caused by strains with an MIC ≥1.5 mg/L had a greater probability of treatment failure than bacteraemia caused by strains with lower MICs (40% versus 23%). This correlation was based on MICs obtained only by the Etest and the report did not offer information about microdilution. Similar results were published by Lodise et al., 13 who observed that MRSA bacteraemia caused by strains with an MIC ≥1.5 mg/L was associated with more frequent admission to the ICU, prolonged hospital stay and twice the rate of treatment failure (36.4% versus 15.4%). This study also used the Etest and vancomycin serum levels were only available for 53 out of 92 patients. Moreover, Holmes et al. 27 recently described an increased mortality in 523 patients with S. aureus bacteraemia with vancomycin MIC ≥2 mg/L measured by Etest. Those authors included 324 patients with methicillin-susceptible S. aureus treated or not with vancomycin (26.8% versus 12.2%; P ¼ 0.001). 27 Other authors, however, did not find this correlation, even when they reported somehow discordant results. 28, 29 A prospective study in England including 100 patients with MRSA bacteraemia (45 treated with vancomycin) found that mortality at 3 months was higher in infections caused by isolates with an MIC ,1.5 mg/L by the Etest compared with a higher MIC (OR, 12; 95% CI, 1.73-83.2). 28 In another retrospective study, Lalueza et al. 29 examined 63 patients with MRSA bacteraemia treated with vancomycin. They found that patients with strains with an Etest MIC ≥1.5 mg/L exhibited lower levels of systemic inflammatory response and that MIC did not have any impact on mortality. 29 The results of our study suggest that vancomycin MIC is not a decisive factor in the clinical outcome of patients with MRSA bacteraemia. We were unable to demonstrate a clinical correlation with MIC values obtained by the Etest or microdilution. The features that correlated with a poor outcome were prognosis of the underlying conditions (McCabe and Jackson score), high Charlson comorbidity index and sepsis score, and renal failure during the episode of bacteraemia. High trough levels of vancomycin are recommended in order to obtain an AUC/MIC .400, which has been associated with a better response to treatment. 10, 30, 31 However, in our study we were unable to reproduce these results. We did not find a relationship between serum levels and clinical outcome, although patients with serum vancomycin concentrations .20 mg/L showed a trend for higher mortality (27% versus 13%; P¼ 0.007). A possible explanation could be that higher vancomycin levels may be the consequence of renal failure, which was an independent factor associated with mortality in the multivariate analysis.
Our study has certain limitations. Due to its retrospective design we did not evaluate the association between clinical response and the AUC/MIC of vancomycin. A prospective study is necessary to confirm whether AUC/MIC .400 is associated with a better response to treatment, as other authors have reported. 10, 30, 31 We only had a small sample size with MICs ≥2 mg/L by Etest. It would be necessary to have a larger sample size to know if MICs ≥2 mg/L by Etest are related with mortality in MRSA bacteraemia. Finally, the strains were stored at 2708C and this could have altered the vancomycin MICs, as recently reported by Edwards et al. 32 In our opinion our inclusion criterion of requiring at least one available vancomycin serum level is a strength of our study.
Our study suggests that there is a poor correlation between vancomycin MIC values obtained by microdilution and by the Etest. We did not find an association between the mortality rate and any MIC value, not even in patients with suboptimal vancomycin trough serum levels. Our data do not support replacing or complementing the standard microdilution method with the Etest for the determination of vancomycin MICs in 
